Aethlon Medical, Inc.

AEMD · NASDAQ

AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matter.

Follow Add to Watchlist Ask Question

NASDAQ AEMD Coverage Bootstrap Medical Devices Clinical Stage Hemopurifier

Latest ReportMay 14, 2026Aethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.